Research Output

2021 2021 2020 2020 2019 2019 0.0 0.0 0.2 0.2 0.4 0.4 0.6 0.6 0.8 0.8 1.0 1.0
Now showing 1 - 2 of 2
No Thumbnail Available
Publication

Correction for Khan et al., “A Multicenter Study To Evaluate Ceftaroline Breakpoints: Performance in an Area with High Prevalence of Methicillin-Resistant Staphylococcus aureus Sequence Type 5 Lineage”

2021 , Ayesha Khan , Lina M. Rivas , Maria Spencer , Rodrigo Martinez , Marusella Lam , Pamela Rojas , PORTE TORRE, LORENA ISABEL , Francisco Silva , Stephanie Braun , Francisca Valdivieso , Margareta Mϋlhauser , Mónica Lafourcade , William R. Miller , Patricia García , Cesar A. Arias , MUNITA SEPULVEDA, JOSE MANUEL

No Thumbnail Available
Publication

A Multicenter Study To Evaluate Ceftaroline Breakpoints: Performance in an Area with High Prevalence of Methicillin-Resistant Staphylococcus aureus Sequence Type 5 Lineage

2019 , Ayesha Khan , Lina M. Rivas , Maria Spencer , Rodrigo Martinez , Marusella Lam , Pamela Rojas , PORTE TORRE, LORENA ISABEL , Francisco Silva , Stephanie Braun , Francisca Valdivieso , Margareta Mv̈lhauser , Mónica Lafourcade , William R. Miller , Patricia García , Cesar A. Arias , MUNITA SEPULVEDA, JOSE MANUEL , Robin Patel

Ceftaroline (CPT) is a broad-spectrum agent with potent activity against methicillin-resistant Staphylococcus aureus (MRSA). The sequence type 5 (ST5) Chilean-Cordobés clone, associated with CPT nonsusceptibility, is dominant in Chile, a region with high rates of MRSA infections.